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Abstract
Background: Depressive symptoms in old age are common, but the prevalence, persistence, and incidence of
depressive symptoms in older adults with and without dementia receiving in-home care is less well studied, and
descriptions of the relationship between severity of cognitive decline and depressive symptoms over time is, to our
knowledge, lacking. The aim of the present study was to describe the prevalence, incidence and persistence of
depressive symptoms over a 36-month follow-up period among older adults receiving in-home care at baseline,
and to explore the association between cognitive function and the course of depressive symptoms over time.
Methods: In all, 1001 older people (≥ 70 years) receiving in-home care were included in a longitudinal study with
three assessments over 36 months. Depressive symptoms were assessed using the Cornell Scale for Depression in
Dementia. Clinical Dementia Rating Scale, diagnosis of dementia and mild cognitive impairment, general medical
health, personal and instrumental activities of daily living, neuropsychiatric symptoms and the use of psychotropic
medication were evaluated during the three assessments. Baseline demographic characteristics and information on
nursing home residency at follow-up were recorded. Linear mixed models were estimated.
Results: The baseline prevalence and cumulative incidence of single depressive symptoms were higher in those
with dementia at baseline than in those without dementia. The persistence of depressive symptoms did not differ
between those with or without dementia at baseline. The severity of cognitive impairment and mean depressive
symptom score assessed simultaneously were positively associated, but the strength of the association changed
over time and was not significant at the last assessment. Furthermore, being younger, female, in very poor physical
health, with neuropsychiatric symptoms and not becoming a nursing home resident were associated with more
depressive symptoms when assessed simultaneously.
Conclusion: The baseline prevalence and cumulative incidence of depressive symptoms in those with and without
dementia at baseline, as well as the relationship we found between the degree of cognitive decline and depressive
symptoms over time show that depression and dementia are interconnected. Nurses and clinicians should pay
attention to cognitive status when observing or evaluating depression among older adults receiving in-home care.
Keywords: Cognitive decline, CSDD, Depressive symptoms, Depression, Domiciliary care, Elderly, Home care,
Neuropsychiatric inventory, Symptom load, Physical disease
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Introduction
Depression is a frequent cause of emotional suffering in
old age, and it may also contribute to reduced physical
functioning, reduced quality of life [1–3], increased risk
of nursing home admission [4], and reduced life expect-
ancy [5, 6]. Depression in old age is also related to
higher health care costs [7].
A population-based meta-analysis found the diagnostic
pooled prevalence of depression in older adults to be
about 7% [8]. A review of population-based studies of
older adults with mild cognitive impairment (MCI) re-
ported the prevalence of diagnosed depression in these
studies to vary between 11 and 40% [9]. In a European
study that included data from older adults with dementia
in eight countries who were receiving in-home care, the
pooled prevalence of clinically significant depressive
symptoms, defined as ≥10 on the Cornell Scale for De-
pression in Dementia, was 34% [10]. The prevalence of
clinically significant depressive symptoms in older adults
with dementia receiving in-home care varied from 11 to
60% between countries [10, 11]. In some countries the
reported prevalence was higher in individuals receiving
in-home care than in nursing home (NH) residents [10],
but not in all [10, 11]. The prevalence of depression and
clinically significant depressive symptoms, as well as the
persistence, incidence and remission of depression and
depressive symptoms has been extensively explored in
NH residents [12, 13], compared to older adults who live
at home and receive care. To our knowledge, there are
no reports of studies that provide a detailed description
of the prevalence, persistence, incidence and remission
of individual depressive symptoms in older adults receiv-
ing in-home care in the Nordic countries or Norway.
However, this information is important for politicians
and health care planners in these countries as they plan
for providing adequate care for older adults in need of
in-home care. The Cornell Scale for Depression in De-
mentia (CSDD) [14], which is validated for use in people
with and without dementia [14–17] and is widely used
in clinical settings and research [18–20], is a useful tool
to assess depressive symptoms among older adults re-
ceiving in-home care.
A review of studies of the course of depression in com-
munity dwelling and general practice people has reported
that one of three people develop a chronic depressive
course [21]. The same review found that factors associated
with persistent depression in older community-dwelling
residents were greater age, high external locus of control
and baseline physical co-morbidity, functional limitations,
and more severe depressive symptoms, but the evidence
was inconclusive when it came to an association between
dementia and persistent depression [21]. However, de-
mentia and depression commonly coexist [22], and both a
history of depression and use of antidepressants have in
reviews been found linked to increased risk for dementia
[23, 24]. Furthermore, depressive symptoms may present
somewhat differently in people with dementia compared
to people without dementia [25]. Not all people with MCI
develop dementia, but a review of studies exploring de-
pression in older adults with MCI concluded that MCI
could be the earliest identifiable clinical stage of dementia,
and argued that the underlying neuropathological condi-
tion causing MCI or dementia may also cause depressive
symptoms [9]. It is possible that late-life depression could
be an early cause prodromal sign of dementia, especially
because pathological changes associated with dementing
diseases can begin long before their clinical onset [6].
Thus, the course of depressive symptoms in older adults
receiving in-home care is of particular interest and may
give us a better understanding of the relationship between
cognitive decline, and the course of depressive symptoms.
In clinical practice, dementia may be mistaken for depres-
sion due to lack of initiative and limitations in personal
and instrumental activities of daily living.
To explore the course of depressive symptoms, we
have carried out a longitudinal, large-scale study of a
group of older adults receiving in-home care at baseline,
with three assessments over 36 months. The first aim of
our study was to describe the prevalence, incidence and
persistence of depressive symptoms over the follow-up
period, and the second aim was to explore the associ-
ation between cognitive function and the course of
depressive symptoms. A detailed description of the
prevalence, persistence, incidence and remission of indi-
vidual depressive symptoms in older adults receiving in-
home care is of clinical importance for nurses and other
caregivers providing the in-home care. Furthermore, it is
of interest to explore the relationship between cognitive
functioning and depressive symptoms to improve treat-
ment and follow-up. Politicians and health care planners
will favour such knowledge to provide sufficient care for
older adults in need of in-home care.
Methods
Study design
This longitudinal study, with a 36-month follow-up
period, collected baseline information between August
2008 and December 2010. The follow-up assessments
were after 18 and 36 months, last follow-up January
2014 [26].
Participants
In total, 1796 individuals (age ≥ 70 years) from 19 small,
medium and large municipalities in five counties in the
eastern part of Norway were invited to participate in the
study. All participants had to be receiving in-home care,
aged ≥70 years and have a next of kin who saw them at
least once a week. No further exclusion criteria were
Helvik et al. BMC Geriatrics          (2019) 19:231 Page 2 of 14
included. Participants were both established and new
users of in-home care. Established users were drawn
from the lists of care service providers and new users
were included successively. These services could typic-
ally include ‘meals on wheels’, safety alarm, practical aid,
day-care centre, mental health care or in-home nursing.
The individuals were invited regardless of amount and
kind of service received.
Of the total 1796 people invited, 795 declined to par-
ticipate, leaving 1001 people in the study. Those who de-
clined participation were more often female and older
than those included in the study [26, 27].
Measures
Depressive symptoms (dependent variable) were assessed
with the Cornell Scale for Depression in Dementia
(CSDD) at all assessments [14]. The CSDD was scored
by a research assistant after an interview with the pa-
tient’s primary caregiver. The CSDD consists of 19
items, with each item rated as 0 (absent), 1 (mild), 2 (se-
vere) or “symptom is not possible to evaluate”. If more
than 20% of the items in CSDD were scored as “not pos-
sible to evaluate”, the participant was excluded from the
analysis, otherwise the item response was set to missing.
Since symptoms that are not possible to evaluate may
contribute to reducing the sum-score, a mean-score of
the scale was used. A clinically significant symptom level
indicating depression was defined as a mean CSDD
score higher than 0.42, which is equivalent to a sum-
score cut-off of 9 and higher for CSDD.
The levels of personal and instrumental functioning
were reported by next of kin and classified using Lawton
and Brody’s Physical Self-Maintenance Scale (P-ADL)
and Instrumental Activities of Daily Living Scale (I-
ADL). The P-ADL sum-score is based on six items
(range 6–30), where higher scores indicate a lower level
of functioning, while the I-ADL sum-score is based on
eight items (range 0–8), where a higher score indicates
better I-ADL functioning [28]. These scales are among
the shorter scales that are recommended to assess P-
ADL and I-ADL [29], are frequently used in Norwegian
and Scandinavian studies [30, 31] and are suitable for
use in community-living older persons as well as in NH
residents [32, 33].
Cognitive function and dementia severity symptoms
were evaluated by the following tools: Mini-Mental State
Examination (MMSE) [34], Clock-Drawing Test (CDT)
[35], the Informant Questionnaire on Cognitive Decline
in Elderly (IQCODE) [36] and Clinical Dementia Rating
Scale (CDR). The CDR includes six domains; memory,
orientation, judgement and problem solving, community
affairs, home functions, and personal care. An algorithm
gives a total score of 0, 0.5, 1, 2 or 3, indicating respect-
ively; no dementia, possible dementia, and mild,
moderate and severe dementia [37]. In the present study,
we used CDR sum of boxes (CDR-SoB), with a score
ranging from 0 to 18, where a higher score indicates
more severe cognitive decline [38]. The assessment tools
for cognitive function and severity of dementia have
been translated and validated in Norwegian [39–41].
The research assessors completed the CDR scale based
on all collected information.
Neuropsychiatric symptoms were evaluated using the
Neuropsychiatric Inventory (10-item NPI) [42] in a trans-
lated and validated Norwegian version [43]. The 10-item
version covers the following symptoms: delusion, hallucin-
ation, euphoria, agitation/aggression, disinhibition, irrit-
ability/lability, depression/dysphoria, anxiety, apathy/
indifference, and aberrant motor behaviour. Three sub-
syndromes of NPI; “Agitation”, “Psychosis”, and “Affective
symptoms”, have previously been reported using the sam-
ple in the present study [44]. “Agitation” includes the
items agitation/aggression, euphoria, disinhibition, aber-
rant motor behaviour and irritability; “psychosis” includes
the items delusions and hallucinations. “Affective symp-
toms” includes the items depression, anxiety, and apathy.
Dementia and mild cognitive impairment (MCI) were di-
agnosed independently by two experienced physicians in
geriatric psychiatry at all three assessments based on all
available information. Diagnoses of dementia were made
according to the ICD-10 criteria [45] and MCI according to
the Winblad criteria [46]. In cases of disagreement, consen-
sus was reached after consulting a third clinical expert.
Physical health was evaluated using the General Med-
ical Health Rating Scale (GMHR), considering the pa-
tient’s number and severity of medical conditions and
the use of medication due to these conditions. GMHR is
scored from 1 to 4, where 1 indicates very poor physical
health and 4 indicates good physical health [47].
Data on the participants’ use of drugs were collected
from medical records. Drugs were divided into groups ac-
cording to the Anatomical Therapeutic Chemical (ATC)
Classification System [48]. Psychotropic drugs were cate-
gorized as antipsychotics (N05A except lithium), anxio-
lytics (N05B), hypnotics/sedatives (N05C), antidepressants
(N06A), and anti-dementia medication (N06D). Use of
medication was dichotomized into yes or no. Medication
dosages were not available for the present study.
The formal level of care at follow-up assessments was
recorded as location, i.e. community-dwelling receiving
in-home care or NH care.
Demographic data including age, gender, municipality
of residence and marital status were recorded in the
baseline assessment.
Procedure
The process of collecting data was led by a research
nurse who cooperated with assessors in the different
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municipalities. The majority of the assessors were
nurses, social educators and occupational therapists. All
assessors took a two-day training course on how to use
the assessment scales before the baseline data collection
began. A one-day training course was conducted prior
to the second and third assessments. The participants
and their next of kin were interviewed simultaneously by
two separate research assessors. Further information re-
garding the data collection is published elsewhere [27].
Study information, both oral and written, was given to
the participants and their next of kin. Written informed
consent was required from both the participant and their
next of kin before the interviews were carried out. In
those lacking capacity to consent, their closest family
proxy gave their informed consent on behalf of their
next of kin. The Regional Committee for Medical and
Health Research Ethics for Eastern Norway (S-08111b),
the Norwegian Social Science Data Services (NSD) (07–
2008SI), and the Directorate for Health and Social Af-
fairs (08/2984) approved this study.
Data analysis
Sample characteristics at baseline were presented as
means and standard deviations (SD) or as frequencies
and percentages. For analyses on the course of depres-
sive symptoms, the 19 CSDD items were dichotomized
to present (rating of 1 or 2) or absent (rating of 0).
Prevalence, incidence, cumulative incidence and persist-
ence were calculated for each depressive symptom and
compared between participants with dementia and par-
ticipants without dementia with a generalized linear
mixed-model adjusted for within-municipality correla-
tions. Prevalence was defined as the proportion of
residents with the symptom present at an individual as-
sessment. Incidence rate was defined as the ratio of resi-
dents who presented the symptom at one assessment to
those who were symptom free at the preceding assess-
ment. Cumulative incidence was reported as incidence
throughout the whole study period. Persistence rate was
calculated as the ratio of residents who presented the
symptom at one assessment to those who presented the
symptom at the preceding assessment.
To assess if the severity of the cognitive impairment/
dementia (CDR-SoB) was associated with mean depres-
sive symptoms (CSDD) over time, two linear mixed
models were estimated. Model 1 for CSDD measured at
baseline contained fixed effects for baseline CDR-SoB,
while CDR-SoB measured simultaneously with longitu-
dinally assessed CSDD was included as a fixed effect in
Model 2. Bivariate models with time, CDR-SoB and
interaction between those two were estimated first. Next,
the models were adjusted for pre-defined covariates
(gender, age, single, GMHR, P-ADL, I-ADL, Neuro-
psychiatric sub-syndrome score for Agitation, Psychosis
and Affective, use of antipsychotics, antidepressants, an-
xiolytics, sedatives, and cognitive enhancers in both
models; admission to NH only in Model 2) one at the
time. Covariates measured at baseline were included in
Model 1, while covariates measured simultaneously with
CSDD whenever possible were included in Model 2. In
this way, Model 2 takes into account the dynamics in
both outcome and covariates. Finally, multiple models
that included all covariates were estimated and reduced
by applying Akaike’s Information Criterion (AIC), where
a smaller value means a better model. All models con-
tained random intercepts for participants nested within
municipality and random slope for time. Prior to regres-
sion analyses, correlations among assessed variables were
evaluated to identify possible multicollinearity issues.
Statistical analyses were performed in SAS v 9.4 and




Of the 1001 participants at baseline (T1), 46 (4.5%) were ex-
cluded due to missing data for CSDD (20% or more of single
items were not possible to evaluate) at baseline. Among the
remaining 955 participants, 394 (41.2%) had dementia, 266
(27.9%) had MCI and 295 (30.9%) had no cognitive impair-
ment at baseline, and the mean (SD) age was 83.4 (5.6) years
(see Table 1). In all, 653 (68.4%) of the participants were
women, 287 (30.1%) were married and 149 (15.6%) had a
good physical health based on the GMHR. The mean (SD)
baseline CDR-SoB was 3.2 (3.8). At follow-up, 511 (53.5%)
and 417 (43.7%) of the 955 participants analysed at baseline
were available for analyses at the second and third assess-
ments (T2 and T3), respectively (see Fig. 1). At follow-up, 82
participants (16.1%) and 100 participants (24.0%) had been
admitted to a NH at T2 and T3, respectively.
Prevalence, incidence and persistence of single symptoms
of depression and clinically significant symptom levels
The prevalence of depressive symptoms at baseline and at
follow-up is presented in Table 2. The two most prevalent
single symptoms reported by the CSDD at baseline were
anxiety (35.9%), and multiple physical complaints (35.2%).
The prevalence at T2 and T3 were 36.3 and 33.5%, and 37.5
and 29.8% for anxiety and multiple physical complaints, re-
spectively. At all assessments, anxiety symptoms were sig-
nificantly more prevalent in participants with dementia at
baseline than in those without dementia (MCI or no cogni-
tive impairment). The prevalence of multiple physical com-
plaints did not differ between residents with and without
dementia for any assessment. The least frequent symptoms
at baseline were delusion (5.6%), suicidal ideation (5.6%) and
agitation (5.8%) and the prevalence of these symptoms was
quite similar at T2 and T3. At baseline, 19.3% had a clinically
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significant symptom level indicating depression, i.e. a mean
CSDD score higher than 0.42, which was equivalent to a
sum-score cut-off of 9 and higher at CSDD. The cumulative
incidence of a clinically significant symptom level after base-
line was 15.6%. The cumulative incidence of eight items on
the CSDD scale (lack of joy, irritability, retardation, lack of
interest, multiple awakening, early morning awakening, poor
self-esteem and delusions) was higher for those with demen-
tia than without dementia.
The persistence of clinically significant levels of de-
pressive symptoms between T1 and T2 was 34.7%,
while the persistence between T2 and T3 was 24.6%.
Only one depressive symptom, irritability, was more
persistent between T1 and T2 for those with dementia
at baseline (65.8%) than for those without (43.9%).
The symptom pessimism was more persistent between
T2 and T3 in those without dementia at baseline
compared to those with dementia, i.e. 58.1 and 30.3%,
respectively.
Mean depressive symptoms score over the follow-up
period
The overall mean CSDD score decreased over the 36-
month follow-up (Table 3 and Fig. 2). Unadjusted for
covariates, there was a significant linear reduction in
mean CSDD score through the study period (p = 0.015),
by an average of 0.001 points per month.
Association between dementia and mean depressive
symptom score
The association between the severity of cognitive decline,
assessed with the CDR-SoB and the mean CSDD score
over time was studied in two multiple models. In multiple
Model 1 (see Table 4), the association between CDR-SoB
Table 1 Sample characteristics at baseline (N = 955)
All
N = 955







Age Mean (SD) 83.4 (5.6) 81.7 (5.6) 83.4 (5.4) 84.6 (5.5)
Females N (%) 653 (68.4) 202 (68.5) 188 (70.7) 263 (66.8)
Marrieda N (%) 287 (30.1) 81 (27.5) 80 (30.2) 126 (32.0)
Health condition
GMHRa
Good N (%) 149 (15.6) 67 (22.7) 42 (15.8) 40 (10.2)
Fairly good N (%) 378 (39.6) 127 (43.1) 109 (41.0) 142 (36.1)
Poor N (%) 326 (34.2) 80 (27.1) 93 (35.0) 153 (38.9)
Very Poor N (%) 101 (10.6) 21 (7.1) 22 (8.3) 58 (14.8)
P-ADL scoreb Mean (SD) 9.1 (3.5) 7.6 (2.1) 8.4 (3.0) 10.8 (4.0)
I-ADL scoreb Mean (SD) 5.2 (2.4) 6.6 (1.6) 5.9 (2.0) 3.6 (2.2)
CDR-SoB Mean (SD) 3.2 (3.8) 0.8 (1.4) 1.6 (2.0) 6.1 (4.0)
Neuropsychiatric
sub-syndrome score
Agitationc Mean (SD) 1.7 (4.6) 0.7 (2.7) 1.1 (3.1) 2.8 (6.1)
Psychosisc Mean (SD) 0.5 (2.0) 0.1 (0.5) 0.2 (1.5) 1.1 (2.8)
Affectivec Mean (SD) 2.9 (5.3) 1.1 (2.6) 2.2 (3.9) 4.7 (6.8)
Use of psychotropic
medication
Antipsychotics N (%) 36 (3.8) 5 (1.7) 7 (2.6) 24 (6.1)
Antidepressants N (%) 148 (15.5) 32 (10.9) 38 (14.3) 78 (19.8)
Anxiolytics N (%) 84 (8.8) 15 (5.1) 27 (10.2) 42 (10.7)
Sedatives N (%) 211 (22.1) 54 (18.3) 59 (22.2) 98 (24.9)
Cognitive enhancers N (%) 54 (5.7) 0 4 (1.5) 50 (12.7)
No of drugs Mean (SD) 5.4 (2.9) 5.1 (3.1) 5.4 (2.8) 5.5 (2.9)
MCI Mild Cognitive Impairment, GMHR General Medical Health Rating Scale, P-ADL Personal functioning assessed with Lawton and Brody’s Physical Self-Maintenance
Scale, I-ADL Instrumental functioning assessed with Instrumental Activities of Daily Living Scale, CDR-SoB Clinical Dementia Rating Scale with sum of boxes
aMissing information from one participant
bMissing information from three participants
cMissing information from two participants
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at T1 and mean CSDD score changed over time (p < 0.001
for interaction). More severe cognitive impairment was as-
sociated with a higher mean CSDD score at T1, with the
association significant for values of CDR-SoB of 3 or
higher and becoming somewhat stronger with increasing
values of CDR-SoB (p < 0.001). However, this association
was not significant at T2 and at T3 (Fig. 3).
In multiple Model 2, the association between CDR-SoB
and mean CSDD score assessed simultaneously at three
time points also changed over time (p < 0.001 for inter-
action). The association was positive and significant for
values of CDR-SoB of 2 or higher, and became somewhat
stronger with increasing values of CDR-SoB at both T1
and T2 (p < 0.001), but was not significant at T3 (Fig. 4).
In both multiple models, being female, younger, and
having a higher level of agitation and affective sub-syn-
drome score were associated with a higher score on the
CSDD scale. In addition, in multiple Model 1, using
sedatives and having a lower I-ADL score at baseline were
associated with higher score on the CSDD scale through-
out the follow-up. In Model 2, having very poor, as com-
pared to good, physical health and not being a NH
resident at T2 and T3 were associated with a higher score
on the CSDD scale when measured simultaneously.
Discussion
The present study describing the prevalence, incidence
and persistence of depressive symptoms over a 36-
month follow-up period among older adults receiving
in-home care at baseline, and found that both the base-
line prevalence and cumulative incidence of depressive
symptoms were higher in those with dementia at base-
line than in those without dementia at baseline. How-
ever, the persistence of single depressive symptoms did
not differ between those with or without dementia at
baseline. When exploring the association between cogni-
tive impairment and the course of depressive symptoms
over time, we found a positive association between the
severity of cognitive impairment and mean depressive
symptoms assessed simultaneously. Furthermore, we
found that the association changed over time and was
not significant at the last follow-up, 36 months after
baseline. In the same analysis, being younger, female, in
very poor physical health, with more neuropsychiatric
symptoms and not being a NH resident were also associ-
ated with higher mean depressive symptoms. This is the
first study exploring depressive symptoms over time in
older people receiving in-home care at inclusion.
When looking at single symptoms assessed with
CSDD, most symptoms at baseline were more com-
mon in participants with dementia than in partici-
pants without dementia. However, the differences in
prevalence of single symptoms among those with and
without dementia at baseline were reduced over the
36-month follow-up. This might be explained by an
increased cognitive decline both in those with and
Fig. 1 Flowchart for participants over 36 months
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Table 2 Prevalence, incidence and persistence of depressive symptoms (CSDD-items) by the presence of dementia at baseline
CSDD items Prevalence
T1 T2 T3
All nD / D All nD / D All nD / D
n/N (%) n (%) / n (%) n/N (%) n (%) / n (%) n/N (%) n (%) / n (%)
Anxiety 339/945 (35.9) 169 (30.3) / 170 (43.8)*** 184/507 (36.3) 92 (30.4) / 92 (45.1)** 137/409 (33.5) 76 (28.5) / 61 (43.0)*
Sadness 273/951 (28.7) 124 (22.2) / 149 (37.9)*** 134/509 (26.3) 66 (21.6) / 68 (33.5)* 99/409 (24.2) 62 (23.2) / 37 (26.1)
Lack of Joy 149/951 (15.7) 52 (9.3) / 97 (24.7)*** 87/509 (17.1) 33 (10.8) / 54 (26.5)*** 66/411 (16.1) 38 (14.2) / 28 (19.6)
Irritability 244/949 (25.7) 107 (19.2) / 137 (34.9)*** 149/510 (29.2) 57 (18.6) / 92 (45.3)*** 104/411 (25.3) 64 (23.9) / 40 (28.0)
Agitation 55/954 (5.8) 20 (3.6) / 35 (8.9)** 27/510 (5.3) 7 (2.3) / 20 (9.9)*** 19/413 (4.6) 12 (4.4) / 7 (4.9)
Retardation 160/949 (16.9) 50 (8.9) / 110 (28.4)*** 82/509 (16.1) 30 (9.8) / 52 (25.7)*** 64/412 (15.5) 29 (10.8) / 35 (24.3)***
Multiple physical
complaints
333/947 (35.2) 197 (35.2) / 136 (35.1) 190/506 (37.5) 110 (36.1) / 80 (39.8) 122/410 (29.8) 78 (29.2) / 44 (30.8)
Lack of interest 164/948 (17.3) 52 (9.3) / 112 (28.8)*** 82/507 (16.2) 33 (10.8) / 49 (24.4)*** 55/407 (13.5) 26 (9.8) / 29 (20.6)**
Appetite loss 215/952 (22.6) 91 (16.3) / 124 (31.6)*** 88/507 (17.4) 45 (14.8) / 43 (21.2) 64/412 (15.5) 43 (16.0) / 21 (14.7)
Weight loss 146/941 (15.5) 65 (11.7) / 81 (21.0)*** 53/500 (10.6) 31 (10.2) / 22 (11.2) 43/408 (10.5) 30 (11.3) / 13 (9.1)
Lack of energy 265/948 (28.0) 125 (22.3) / 140 (36.2)*** 107/508 (21.1) 54 (17.6) / 53 (26.2)* 84/408 (20.6) 54 (20.2) / 30 (21.3)
Diurnal variation 85/918 (9.3) 37 (6.9) / 48 (12.7)** 72/487 (14.8) 30 (10.3) / 42 (21.3)** 44/397 (11.1) 23 (9.0) / 21 (14.8)
Difficulty falling asleep 171/922 (18.5) 101 (18.7) / 70 (18.4) 63/492 (12.8) 41 (13.8) / 22 (11.3) 62/395 (15.7) 42 (16.3) / 20 (14.5)
Multiple awakening 225/882 (25.5) 122 (23.3) / 103 (28.8) 120/478 (25.1) 58 (20.1) / 62 (32.8)** 94/386 (24.4) 60 (23.9) / 34 (25.2)
Early morning
awakening
117/923 (12.7) 56 (10.2) / 61 (16.2)* 55/494 (11.1) 25 (8.4) / 30 (15.2)* 41/394 (10.4) 24 (9.5) / 17 (12.1)
Suicidal ideation 53/954 (5.6) 20 (3.6) / 33 (8.4)** 22/508 (4.3) 10 (3.3) / 12 (6.0) 16/404 (4.0) 10 (3.8) / 6 (4.3)
Poor self-esteem 128/945 (13.5) 61 (11.0) / 67 (17.3)* 80/511 (15.7) 35 (11.4) / 45 (22.1)** 55/402 (13.7) 31 (11.7) / 24 (17.4)
Pessimism 230/954 (24.1) 113 (20.2) / 117 (29.7)** 121/503 (24.1) 67 (22.0) / 54 (27.1) 73/403 (18.1) 55 (20.8) / 18 (13.0)
Delusions 53/951 (5.6) 18 (3.2) / 35 (9.0)*** 22/507 (4.3) 6 (2.0) / 16 (7.9)** 19/401 (4.7) 8 (3.1) / 11 (7.9)*
Cut-off> 0.42a 184/955 (19.3) 68 (12.1) / 116 (29.4)*** 103/511 (20.2) 47 (15.3) / 56 (27.5)** 68/417 (16.3) 42 (15.4) / 26 (17.9)
CSDD items Incidence
Cumulative T1-T2 T2-T3
All nD / D All nD / D All nD / D
n/N (%) n (%) / n (%) n/N (%) n (%) / n (%) n/N (%) n (%) / n (%)
Anxiety 126/606 (20.8) 72 (18.6) / 54 (24.8) 83/313 (26.5) 47 (22.6) / 36 (34.3) 54/230 (23.5) 27 (16.5) / 27 (40.9)***
Sadness 121/678 (17.8) 74 (17.1) / 47 (19.3) 66/364 (18.1) 38 (16.1) / 28 (21.9) 52/267 (19.5) 34 (18.4) / 18 (22.0)
Lack of Joy 98/802 (12.2) 48 (9.5) / 50 (16.9)** 59/426 (13.8) 25 (9.1) / 34 (22.4)*** 37/295 (12.5) 22 (10.9) / 15 (16.1)
Irritability 122/705 (17.3) 64 (14.2) / 58 (22.7)** 73/375 (19.5) 31 (12.5) / 42 (33.1)*** 41/254 (16.1) 29 (15.8) / 12 (16.9)
Agitation 37/899 (4.1) 17 (3.1) / 20 (5.6) 21/481 (4.4) 6 (2.0) / 15 (8.2)** 11/327 (3.7) 7 (3.2) / 4 (3.7)
Retardation 93/789 (11.8) 42 (8.2) / 51 (18.3)*** 52/424 (12.3) 21 (7.6) / 31 (21.2)*** 37/300 (12.3) 18 (8.7) / 19 (20.2)*
Multiple physical
complaints
146/614 (23.8) 93 (25.6) / 53 (21.1) 94/321 (29.3) 59 (29.6) / 35 (28.7) 42/206 (20.4) 27 (19.3) / 15 (22.7)
Lack of interest 86/784 (11.0) 42 (8.3) / 44 (15.9)** 56/415 (13.5) 26 (9.4) / 30 (21.6)** 31/296 (10.5) 16 (7.7) / 15 (17.0)*
Appetite loss 97/737 (13.2) 60 (12.8) / 37 (13.8) 51/388 (13.1) 28 (11.2) / 23 (16.8) 35/295 (11.9) 22 (11.2) / 13 (13.3)
Weight loss 81/795 (10.2) 51 (10.4) / 30 (9.8) 42/421 (10.0) 25 (9.4) / 17 (11.0) 30/304 (9.9) 20 (10.1) / 10 (9.5)
Lack of energy 113/683 (16.5) 68 (15.6) / 45 (18.2) 64/356 (18.0) 32 (13.7) / 32 (26.2)** 49/282 (17.4) 32 (16.8) / 17 (18.5)
Diurnal variation 78/833 (9.4) 39 (7.8) / 39 (11.8) 46/431 (10.7) 19 (7.2) / 27 (16.1)** 17/277 (6.1) 11 (5.8) / 6 (6.9)
Difficulty falling
asleep
71/751 (9.5) 42 (9.5) / 29 (9.3) 34/387 (8.8) 20 (8.7) / 14 (8.9) 35/283 (12.4) 23 (12.4) / 12 (12.4)
Multiple awakening 119/657 (18.1) 61 (15.2) / 58 (22.7)* 68/342 (19.9) 29 (13.6) / 39 (30.2)*** 44/233 (18.9) 30 (18.3) / 14 (20.3)
Early morning
awakening
63/806 (7.8) 28 (5.7) / 35 (11.1)** 40/430 (9.3) 19 (7.2) / 21 (12.7) 19/287 (6.6) 8 (4.2) / 11 (11.2)*
Suicidal ideation 28/901 (3.1) 15 (2.8) / 13 (3.6) 20/482 (4.1) 9 (3.0) / 11 (5.9) 9/324 (2.8) 4 (1.9) / 5 (4.6)
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All nD / D All nD / D All nD / D
n/N (%) n (%) / n (%) n/N (%) n (%) / n (%) n/N (%) n (%) / n (%)
Poor self-esteem 76/817 (9.3) 36 (7.3) / 40 (12.5)* 53/438 (12.1) 24 (8.8) / 29 (17.5)* 25/288 (8.7) 14 (7.0) / 11 (12.5)
Pessimism 96/724 (13.3) 62 (13.9) / 34 (12.3) 67/381 (17.6) 41 (17.0) / 26 (18.6) 24/261 (9.2) 20 (11.2) / 4 (4.8)
Delusions 29/898 (3.2) 10 (1.8) / 19 (5.4)** 14/482 (2.9) 4 (1.4) / 10 (5.3)* 13/323 (4.0) 6 (2.8) / 7 (6.4)
Cut-off> 0.42a 120/771 (15.6) 69 (14.0) / 51 (18.3) 68/410 (16.6) 32 (12.0) / 36 (25.2)* 35/285 (12.3) 25 (12.6) / 10 (11.5)
CSDD items Persistence at two
consecutive time points
T1-T2 T2-T3
All nD / D All nD / D
n/N (%) n (%) / n (%) n/N (%) n (%) / n (%)
Anxiety 99/187 (52.9) 44 (47.8) / 55 (57.9) 62/112 (55.4) 37 (63.8) / 25 (46.3)
Sadness 66/142 (46.5) 27 (39.7) / 39 (52.7) 30/78 (38.5) 18 (45.0) / 12 (31.6)
Lack of Joy 28/82 (34.1) 8 (25.8) / 20 (39.2) 14/49 (28.6) 6 (28.6) / 8 (28.6)
Irritability 75/133 (56.4) 25 (43.9) / 50 (65.8)* 43/91 (47.3) 23 (54.8) / 20 (40.8)
Agitation 6/29 (20.7) 1 (11.1) / 5 (25.0) 4/19 (21.1) 1 (16.7) / 3 (23.1)
Retardation 9/28 (32.1) 2 (22.2) / 7 (36.8) 14/46 (30.4) 6 (31.6) / 8 (29.6)
Multiple physical
complaints
92/180 (51.1) 51 (48.1) / 41 (55.4) 55/139 (39.6) 34 (40.5) / 21 (38.2)
Lack of interest 26/87 (29.9) 7 (24.1) / 19 (32.8) 13/46 (28.3) 5 (33.3) / 8 (25.8)
Appetite loss 36/117 (30.8) 16 (30.8) / 20 (30.8) 13/50 (26.0) 9 (33.3) / 4 (17.4)
Weight loss 9/71 (12.7) 5 (15.2) / 4 (10.5) 4/34 (11.8) 4 (19.0) / 0
Lack of energy 42/148 (28.4) 22 (30.6) / 20 (26.3) 19/62 (30.6) 12 (35.3) / 7 (25.0)
Diurnal variation 22/43 (51.2) 10 (47.6) / 12 (54.5) 13/44 (29.5) 5 (33.3) / 8 (27.6)
Difficulty falling asleep 26/91 (28.6) 19 (32.8) / 7 (21.2) 13/42 (31.0) 11 (39.3) / 2 (14.3)
Multiple awakening 39/104 (37.5) 22 (38.6) / 17 (36.2) 22/74 (29.7) 14 (36.8) / 8 (22.2)
Early morning
awakening
14/56 (25.0) 6 (23.1) / 8 (26.7) 9/39 (23.1) 7 (35.0) / 2 (10.5)
Suicidal ideation 2/26 (7.7) 1 (9.1) / 1 (6.7) 3/16 (18.8) 2 (33.3) / 1 (10.0)
Poor self-esteem 26/69 (37.7) 11 (32.4) / 15 (42.9) 20/52 (38.5) 12 (50.0) / 8 (28.6)
Pessimism 54/121 (44.6) 26 (41.9) / 28 (47.5) 35/76 (46.1) 25 (58.1) / 10 (30.3)*
Delusions 8/23 (34.8) 2 (22.2) / 6 (42.9) 2/14 (14.3) 1 (20.0) / 1 (11.1)
Cut-off> 0.42a 35/101 (34.7) 15 (37.2) / 20 (32.8) 16/65 (24.6) 8 (26.7) / 8 (22.9)
*** p < 0.001; ** p < 0.01; * p < 0.05 (results of generalized linear mixed model adjusting for within-municipality correlations; SAS GLIMMIX procedure)
CSDD Cornell Scale for Depression in Dementia, nD no Dementia, D Dementia
aA mean CSDD score higher than 0.42 was defined as clinically significant symptom level indicating depression, and is equivalent to a sum-score cut-off
of 9 and higher for CSDD
Table 3 CSDD mean score at each time point in total and stratified by dementia status at baseline
T1 T2 T3
All D/nD All D/nD All D/nD
CSD
N 955 394/561 511 204/307 417 145/272
Mean (SD) 0.25 (0.29) 0.34 (0.34) / 0.19 (0.23) 0.24 (0.26) 0.32 (0.30) / 0.18 (0.22) 0.21 (0.26) 0.24 (0.27) / 0.19 (0.26)
CSDD Cornell Scale for Depression in Dementia, nD no Dementia, D Dementia
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without baseline dementia, which would lead to a
more homogenous group of participants. Among
those without dementia at baseline, almost half had
mild cognitive impairment. The turnover rate from
mild cognitive impairment to dementia is high within
the following year in older adults. However, not all
with mild cognitive impairment will get dementia
[49]. The persistence of symptoms at two consecutive
assessments did not differ between those with and
without dementia at baseline. Even so, the cumulative
incidence of several symptoms was higher in those
with dementia at baseline. Most of the symptoms
with a higher cumulative incidence in participants
with dementia (i.e. lack of joy, irritability, retardation,
lack of interest, multiple awakening, early morning
awakening) are classified as non-mood factors in
CSDD [50]. Of these non-mood symptoms, irritability
was a symptom with both a higher cumulative inci-
dence and baseline prevalence in those with dementia
at baseline. Other studies exploring symptoms of de-
pression in older adults have found irritability to be
highly prevalent in community-dwelling residents with
dementia [51], in NH residents where dementia is
very prevalent [52] and in outpatients with dementia
and depression [53]. It can be difficult to determine
whether irritability is a symptom of depression or de-
mentia [52]. Sleep disturbances, including multiple
awakening and early morning awakening, were among
the few symptoms in CSDD where the baseline preva-
lence did not differ between those with and without
dementia, but those with dementia at baseline had a
higher cumulative incidence throughout the follow-up
period. Sleep disturbances can be explained by several
medical conditions in older adults with and without
dementia. However, it is suggested that these symp-
toms should be considered to be unspecific symptoms
of depression in geriatric populations [54, 55]. Poor
self-esteem and delusion are symptoms included in
the CSDD mood factor [50] that had a higher cumu-
lative incidence in those with dementia at baseline
than those without. It might be that some symptoms
both in the non-mood and mood factors of CSDD
have a higher variability in those with baseline de-
mentia than without. Even so, single symptoms were
not adjusted for deaths or loss of follow-up, cognitive
decline or development of dementia during the fol-
low-up period. Additionally, the time between the as-
sessments was more than 1 year.
The prevalence of clinically significant depressive symp-
toms in the present study of older adults with in-home care
needs was 19% at baseline, which is higher than the diag-
nostic pooled prevalence of depression in older adults [8]
and the prevalence reported in general community-dwelling
living residents in Hong Kong [56], but lower than in an
American study of among older people receiving in-home
care (24.1% with depression) [57]. Those with dementia
were more likely to have clinically significant depressive
symptoms than those without dementia at baseline, which
was expected since depression is associated with dementia
[58]. The prevalence was comparable to the prevalence
found with use of CSDD in older adults with dementia re-
ceiving in-home care in other Nordic countries such as
Sweden and Finland (30%) [10], but lower than the preva-
lence the prevalence found in other European countries, in-
cluding Estonia and Germany (49 and 60%, respectively)
[10]. The care needs, the severity of cognitive decline and
prevalence of physical comorbidity in these samples are un-
known. However, we may speculate that due to the political
and cultural similarities in the Nordic countries, both the
type of formal care delivered and the dementia characteris-
tics and physical comorbidity of older people receiving in-
home care are comparable, and thus, it is reassuring that
the prevalence of depression was similar.
In the present study, there was a significant but small
decline in mean depressive symptom score assessed with
CSDD from baseline to the last follow-up. Few longitu-
dinal studies have explored depression in older adults
receiving in-home care, but a decline in depressive
symptom score over time has also been found in
previous studies from the geriatric psychiatry service
[56], and NH setting [52]. As those studies have pointed
out, we do not know if the results are a part of the nat-
ural course of depression when dementia is prevalent, or
are just artefacts [52, 56]. It could be the Hawthorne ef-
fect, namely that being involved in a research context in-
fluences the behaviour of the respondents’ caregiver
and/or research assistants who conduct the interviews.
Thus, some participants may be scored with fewer or
less severe symptoms over time than they actually have.
Even so, the decline in the mean score of depressive
Fig. 2 Time trend in mean CSDD, unadjusted
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symptoms per month was 0.001 and of less clinical
importance.
In the adjusted analysis where both cognitive
impairment and depressive symptoms were assessed
simultaneously (Model 2), more severe cognitive decline
was associated with more severe depressive symptoms.
The association was stronger with more severe cognitive
decline, but only at T1 and T2. This study reports an as-
sociation between the severity of cognitive decline and
the severity of depressive symptoms, and it is reasonable
to believe that the underlying neuropathological
condition causing cognitive decline, MCI and dementia
can also cause depressive symptoms [9]. Shared bio-
logical pathways between depression and dementia such
as vascular disease, increased deposition of beta amyloid
plaques and neuroinflammation have been suggested
[59]. However, the association between cognitive decline
and the severity of depressive symptoms was stronger at
baseline than at T2, and there was no association at T3.
It may be that, as suggested by others, individuals with
the most severe cognitive decline and who are at a later
stage of dementia at the last assessment no longer have
Table 4 Associations between CDR-SoB measured at baseline (Model 1) or longitudinally (Model 2) and CSDD mean scorea
Covariates Model 1 Model 2
Unadjusted models Adjusted AIC-reduced modelb Unadjusted models Adjusted AIC-reduced modelc
Regr.coeff. (SE) p-value Regr.coeff. (SE) p-value Regr.coeff. (SE) p-value Regr.coeff. (SE) p-value
Main variables
Time 0.0006 (0.0006) 0.244 0.0007 (0.0005) 0.191 −0.0002 (0.0005) 0.690 −0.0003 (0.0004) 0.530
CDR-SoB 0.03 (0.002) < 0.001 0.01 (0.003) < 0.001 0.03 (0.002) < 0.001 0.01 (0.002) < 0.001
CDR-SoB*Time −0.0005 (0.0001) < 0.001 −0.0005 (0.0001) < 0.001 − 0.0005 (0.00009) < 0.001 −0.0003 (0.00008) < 0.001
Socio-demographic information
Women 0.04 (0.01) 0.006 0.03 (0.01) 0.027 0.04 (0.01) 0.002 0.03 (0.01) 0.009
Age (years) −0.004 (0.001) < 0.001 −0.004 (0.001) 0.001 −0.005 (0.001) < 0.001 − 0.002 (0.0009) 0.026
Single 0.009 (0.01) 0.515 0.01 (0.01) 0.330
General physical health
GMHR
Very poor 0.08 (0.03) 0.003 0.08 (0.03) 0.002 0.07 (0.02) 0.001
Poor 0.02 (0.02) 0.393 0.04 (0.02) 0.067 0.03 (0.02) 0.054
Fair 0.008 (0.02) 0.635 0.0008 (0.02) 0.968 0.004 (0.02) 0.813
Good – ref. 0
P-ADL 0.0006 (0.002) 0.791 −0.001 (0.002) 0.577
I-ADL −0.003 (0.004) 0.501 −0.008 (0.004) 0.047 0.0005 (0.004) 0.899
Neuropsychiatric sub-syndrome score
Agitation 0.02 (0.001) < 0.001 0.008 (0.001) < 0.001 0.02 (0.001) < 0.001 0.01 (0.001) < 0.001
Psychosis 0.02 (0.003) < 0.001 0.02 (0.003) < 0.001
Affective 0.02 (0.001) < 0.001 0.02 (0.001) < 0.001 0.03 (0.001) < 0.001 0.02 (0.001) < 0.001
Use of psychotropic medication
Antipsychotics 0.004 (0.03) 0.891 −0.02 (0.03) 0.476
Antidepressants 0.03 (0.02) 0.086 0.04 (0.02) 0.032
Anxiolytics 0.009 (0.02) 0.674 0.03 (0.02) 0.113
Sedatives 0.03 (0.01) 0.024 0.03 (0.01) 0.030 0.04 (0.01) 0.006
Cognitive enhancers 0.05 (0.03) 0.079 0.01 (0.03) 0.588
NH resident beforeT3 −0.12 (0.03) < 0.001 −0.07 (0.02) 0.001
AIC Akaike’s Information Criterion, CDR-SoB Clinical Dementia Rating Scale with sum of boxes, CSDD Cornell Scale for Depression in Dementia, GMHR General
Medical Health Rating Scale, P-ADL Personal functioning assessed with Lawton and Brody’s Physical Self-Maintenance Scale, I-ADL Instrumental functioning
assessed with Instrumental Activities of Daily Living Scale, NH Nursing home. Bold p-values are significant
aResults of linear mixed model
After exclusion of cases with at least one missing value on covariates, in Model 1: N = 946 at T1, N = 505 at T2 and N = 412 at T3 and in Model-2: N = 946 at T1, N =
497 at T2 and N = 403 at T3. Random slope for time included
bAdjusted for covariates measured at baseline
cAdjusted for covariates measured simultaneously except for gender, age and living alone
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Fig. 4 Interpretation of Model 2, unadjusted (left) and adjusted (right). CDR: CDR-SoB = Clinical Dementia Rating Scale with sum of boxes
Fig. 3 Interpretation of Model 1, unadjusted (left) and adjusted (right). CDR: CDR-SoB = Clinical Dementia Rating Scale with sum of boxes
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the cognitive capacity necessary to communicate depres-
sive symptoms [52]. In addition, at the last assessment,
only 40% of the original sample was able to participate,
and we may speculate that those surviving the follow-up
period were less likely to have or express depressive
symptoms, even after adjusting for age [52]. Higher age
was associated with less severe depressive symptoms in
our analytic model. Others have explained this as older
adults being “survivors” who are less prone to becoming
depressed [60] or show depressive symptoms [52].
At T2 and T3, 82 and 100 participants were NH resi-
dents, respectively. In the adjusted analysis, NH residents
had lower depressive scores compared to those receiving
in-home care. In line with our results, a European study
that included data from patients from eight countries
found that the prevalence of depression was higher in
older adults with dementia receiving in-home care than in
those admitted to NH [10]. We do not know the reason
for our findings. However, a well-known reason for NH
admission, in addition to poor cognition, impaired activ-
ities of daily living and comorbidity, is mental health prob-
lems, such as depression and other neuropsychiatric
symptoms [61]. Thus, it is likely that treatment, care or
the setting is important for depressive symptoms. Lower
depressive symptom scores in NH residents may be due
to more social interaction in NHs than among those living
at home. Individuals in NH may have received treatment
for their depressive symptoms. Thus, NH residents may
not have depressive symptoms to the same extent as those
receiving in-home care. Moreover, it could be that the pri-
mary caregiver for those living at home rated depressive
symptomatology high due to caregiver distress. Another
possibility is that primary caregivers in NHs do not know
their residents well enough to understand how residents
express their mental states, or this expression is over-
looked, which would be less likely for the primary care-
giver for participants who live at home. This would make
the mean scores lower in NH residents. This needs further
exploration.
Poor physical health is a well-known risk factor for de-
pression [58], and thus, we adjusted for physical health
in our analysis. We found that higher agitation and
affective sub-syndrome score at each time point were in-
dependently associated with higher depressive symptom
scores assessed simultaneously. This was expected since
the CSDD includes items that also may represent neuro-
psychiatric symptoms.
The study has a number of strengths, such as using a
well-known, internationally recognized scale for asses-
sing depressive symptoms [62], a high number of base-
line participants, use of a direct measure of cognitive
functioning, and controlling for several variables of po-
tential importance to the outcome, such as activity of
daily living, physical health, and demographic variables.
Even so, it has some limitations that need to be
described.
First, the study findings should be interpreted with
caution since this is a study about associations and
should not be mixed with causality.
Secondly, our participants were younger and were
more often male than individuals who were not included
[27]. Those who declined to participate may not be at
random. Thus, the representativeness of the sample for
older people receiving in-home care in Norway may be
somewhat hampered. Furthermore, the sample is not
representative for general older people living in a com-
munity, since one inclusion criterion was that the par-
ticipant received in-home care. Thus, caution should be
taken in generalizing the study results.
Thirdly, it is challenging to conduct a longitudinal study
of depressive symptoms in older people with in-home care
needs over a three-year-period. The time between the as-
sessments was 18months and should have been shorter to
give a better understanding of incidence and persistence
of single symptoms from the CSDD among those with
and without dementia. Furthermore, repeated measures of
the same individuals contributes to dependency in the
data. Moreover, the large number who left the study
mainly due to mortality, gives unequal number of observa-
tions per participant, and this, generates imbalance in the
data. In the present study we used linear mixed model,
since this statistics is known to handle imbalanced data of
any degree by including all available data [63]. Further-
more, this statistics allows time-varying covariates to be
included in the model and it review correlations among
repeated measurements well [63].
Conclusion
In the present study, the baseline prevalence and the cu-
mulative incidence of depressive symptoms were higher
in participants with dementia at baseline than in those
without. The severity of cognitive decline and mean de-
pressive symptoms was positively associated, but the as-
sociation became weaker over time. Our study shows
that depression and dementia are interconnected, and
that nurses and clinicians should pay attention to cogni-
tive status when observing or evaluating depression
among older adults receiving in-home care. When de-
mentia is suspected, the individual must be offered a
diagnostic work-up in order to be given the best treat-
ment possible, which also is in line with the national
policy documents [64].
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